Skip to main content
Premium Trial:

Request an Annual Quote

Hitachi to Deliver Response Genetics’ Clinical Sample Testing Tech in Asia-Pacific

NEW YORK (GenomeWeb News) - Response Genetics today said it has struck an agreement with Hitachi Chemical that will allow Hitachi to use its genetic diagnostic testing methods and services for formalin-fixed paraffin-embedded tissue samples in Southeast Asia, Australia, and New Zealand. 
 
Hitachi will also give Response Genetics access to “potential new testing services customers” in Asia for its FFPE clinical sample testing technology, the company said.
 
Response Genetics said it will provide Hitachi with technical information and assistance related to its testing services and the two companies will split the revenues that come from the collaboration.
 
The countries the partnership covers include Japan, North Korea, South Korea, Taiwan, Mongolia, Pakistan, Bangladesh, Sri Lanka, Nepal, Singapore, Malaysia, Indonesia, Brunei, Thailand, Myanmar, Laos, Cambodia, Vietnam, and the Philippines.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.